CR20210271A - Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso - Google Patents

Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso

Info

Publication number
CR20210271A
CR20210271A CR20210271A CR20210271A CR20210271A CR 20210271 A CR20210271 A CR 20210271A CR 20210271 A CR20210271 A CR 20210271A CR 20210271 A CR20210271 A CR 20210271A CR 20210271 A CR20210271 A CR 20210271A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
substituted amino
receptor antagonists
adenosine receptor
quinazoline derivatives
Prior art date
Application number
CR20210271A
Other languages
English (en)
Inventor
Andrew J Hoover
Umar Faruk Mansoor
Thomas H Graham
Ping Liu
Jianping Pan
Uma Swaminathan
Matthew A Larsen
Duane Demong
Christopher W Plummer
Huijun Wang
Amjad Ali
Qiaolin Deng
Aaron Sather
Kun Liu
Yonglian Zhang
Jared Cumming
Elisabeth Hennessy
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69005832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20210271(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CR20210271A publication Critical patent/CR20210271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En su gran cantidad de formas de realizacion, la presente invencion proporciona determinados compuestos de amino triazolo quinazolina 9-sustituidos de la Formula estructural (I): (I), y sales de aquellos farmaceuticamente aceptables, en donde el anillo A, R1 y R2 son como se definen en la presente, composiciones farmaceuticas que comprenden uno o mas de estos compuestos (solos o en combinacion con uno o mas agentes terapeuticamente activos diferentes), y metodos para su preparacion y uso, solos o en combinacion con otros agentes terapeuticos, como antagonistas de receptores A2a y/o A2b, y en el tratamiento de diversas enfermedades, afecciones o trastornos que estan mediadas, al menos en parte, por el receptor de adenosina A2a y/o el receptor de adenosina A2b. <img alt="Drawing" src="http://aplpatentes:48080/IpasWeb/ImageRender/ImageRender.do?imageNbr=1" style="width: 257px; height: 257px;" />
CR20210271A 2018-11-30 2019-11-26 Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso CR20210271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862774077P 2018-11-30 2018-11-30
PCT/US2019/063136 WO2020112700A1 (en) 2018-11-30 2019-11-26 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

Publications (1)

Publication Number Publication Date
CR20210271A true CR20210271A (es) 2021-07-14

Family

ID=69005832

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210271A CR20210271A (es) 2018-11-30 2019-11-26 Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso

Country Status (25)

Country Link
US (2) US11312719B2 (es)
EP (1) EP3886988A1 (es)
JP (1) JP7241871B2 (es)
KR (1) KR102653800B1 (es)
CN (1) CN113329791A (es)
AR (1) AR117164A1 (es)
AU (1) AU2019385905B2 (es)
BR (1) BR112021010427B1 (es)
CA (1) CA3120862C (es)
CL (1) CL2021001406A1 (es)
CO (1) CO2021006888A2 (es)
CR (1) CR20210271A (es)
DO (1) DOP2021000104A (es)
EA (1) EA202191498A1 (es)
EC (1) ECSP21036982A (es)
IL (1) IL283334A (es)
JO (2) JOP20210117A1 (es)
MA (1) MA54298A (es)
MX (1) MX2021006329A (es)
NI (1) NI202100043A (es)
PE (1) PE20211768A1 (es)
PH (1) PH12021551196A1 (es)
SG (1) SG11202105180PA (es)
TW (1) TW202039496A (es)
WO (1) WO2020112700A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
MX2020011528A (es) 2018-05-02 2021-02-09 Navire Pharma Inc Inhibidores heterociclicos sustituidos de ptpn11.
CN112601750B (zh) 2018-08-10 2023-10-31 纳维尔制药有限公司 Ptpn11（shp2）抑制剂
AU2019383948A1 (en) 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JP7558942B2 (ja) 2018-11-30 2024-10-01 コメット セラピューティクス インコーポレイテッド パンテテイン誘導体及びその使用
AU2019388872A1 (en) * 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
WO2022020550A1 (en) * 2020-07-24 2022-01-27 Merck Sharp & Dohme Corp. Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
WO2022020552A1 (en) * 2020-07-24 2022-01-27 Merck Sharp & Dohme Corp. Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
WO2023158626A1 (en) * 2022-02-16 2023-08-24 Merck Sharp & Dohme Llc Adenosine receptor antagonists, pharmaceutical compositions and their use thereof
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
EP4626892A1 (en) * 2022-11-29 2025-10-08 Merck Sharp & Dohme LLC Adenosine a2a and a2b receptor antagonists, pharmaceutical compositions and use thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN120398919B (zh) * 2024-02-01 2026-04-07 福石生物科技(合肥)有限公司 作为wrn抑制剂的螺环衍生物及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2109577A1 (de) 1971-03-01 1972-09-14 Boehringer Mannheim Gmbh Antimikrobiell wirksame Nitrofuran Derivate und Verfahren zur Herstellung derselben
US3957766A (en) 1970-06-19 1976-05-18 Boehringer Mannheim G.M.B.H. Novel nitrofuran compounds and pharmaceutical compositions
US4713383A (en) 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
GB9524395D0 (en) 1995-11-29 1996-01-31 Nickerson Biocem Ltd Promoters
DE19629378A1 (de) 1996-07-20 1998-01-29 Boehringer Ingelheim Kg Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
US6759759B2 (en) 2000-08-29 2004-07-06 Tamagawa Seiki Kabushiki Kaisha Rotary contactless connector and non-rotary contactless connector
KR100687954B1 (ko) 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
AR038366A1 (es) 2001-11-30 2005-01-12 Schering Corp Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
IL161716A0 (en) 2001-11-30 2004-09-27 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
WO2004029056A1 (ja) 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
ES2278353T3 (es) 2003-10-28 2007-08-01 Schering Corporation Procedimiento para preparar 5-amino-pirazolo-(4,3-e)-1,2,4-triazolo(1,5-c)pirimidinas sustituidas.
CA2547248A1 (en) 2003-12-01 2005-06-16 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
US7472383B2 (en) 2004-08-13 2008-12-30 Sun Microsystems, Inc. System and method for providing exceptional flow control in protected code through memory layers
CA2591125A1 (en) 2004-12-21 2006-06-29 Schering Corporation Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP1934227B1 (en) 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
PE20091101A1 (es) 2007-12-18 2009-07-26 Pharminox Ltd AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO
EP2282999B1 (en) 2008-03-04 2014-05-21 Merck Sharp & Dohme Corp. Amino-quinoxaline and amino-quinoline compounds for use as adenosine a2a receptor antagonists
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2509983B1 (en) 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2012135084A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
US8751477B2 (en) 2012-10-05 2014-06-10 Iac Search & Media, Inc. Quality control system for providing results in response to queries
US9495379B2 (en) 2012-10-08 2016-11-15 Veritas Technologies Llc Locality aware, two-level fingerprint caching
WO2014101113A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
US10472347B2 (en) 2014-11-18 2019-11-12 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
WO2016089796A1 (en) 2014-12-04 2016-06-09 Merck Sharp & Dohme Corp. Formulation inhibiting effects of low acid environment
EP3253390B1 (en) 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
WO2016200717A1 (en) 2015-06-11 2016-12-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
WO2016209787A1 (en) 2015-06-26 2016-12-29 Merck Sharp & Dohme Corp. Sustained release formulation and tablets prepared therefrom
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
HUE064141T2 (hu) * 2017-01-20 2024-02-28 Arcus Biosciences Inc Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
AU2018233367B2 (en) 2017-03-16 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
PL3611174T3 (pl) 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
WO2019002606A1 (en) 2017-06-30 2019-01-03 Selvita S.A. ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN112601750B (zh) 2018-08-10 2023-10-31 纳维尔制药有限公司 Ptpn11（shp2）抑制剂
AU2019383948A1 (en) 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
AU2019388872A1 (en) 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
AR117200A1 (es) 2018-11-30 2021-07-21 Syngenta Participations Ag Derivados de tiazol microbiocidas
AR117183A1 (es) 2018-11-30 2021-07-14 Syngenta Crop Protection Ag Derivados de tiazol microbiocidas

Also Published As

Publication number Publication date
BR112021010427B1 (pt) 2022-09-27
AR117164A1 (es) 2021-07-14
JOP20210117A1 (ar) 2023-01-30
KR102653800B1 (ko) 2024-04-01
NI202100043A (es) 2021-08-13
TW202039496A (zh) 2020-11-01
ECSP21036982A (es) 2021-06-30
EP3886988A1 (en) 2021-10-06
MA54298A (fr) 2022-03-09
PE20211768A1 (es) 2021-09-07
US20210107904A1 (en) 2021-04-15
US20220220117A1 (en) 2022-07-14
JOP20210116A1 (ar) 2023-01-30
JP2022511441A (ja) 2022-01-31
CA3120862C (en) 2024-05-07
IL283334A (en) 2021-07-29
SG11202105180PA (en) 2021-06-29
JP7241871B2 (ja) 2023-03-17
BR112021010427A2 (pt) 2021-08-17
WO2020112700A1 (en) 2020-06-04
DOP2021000104A (es) 2021-07-30
AU2019385905A1 (en) 2021-06-03
PH12021551196A1 (en) 2021-11-29
AU2019385905B2 (en) 2023-01-12
CN113329791A (zh) 2021-08-31
MX2021006329A (es) 2021-08-11
CL2021001406A1 (es) 2021-11-12
CA3120862A1 (en) 2020-06-04
US11312719B2 (en) 2022-04-26
KR20210096184A (ko) 2021-08-04
CO2021006888A2 (es) 2021-06-10
US12060357B2 (en) 2024-08-13
EA202191498A1 (ru) 2021-08-20

Similar Documents

Publication Publication Date Title
CR20210271A (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
MX2021006012A (es) Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
MX393395B (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
AR107751A1 (es) Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
EA202192093A1 (ru) Пиразолопиридины и триазолопиридины в качестве ингибиторов a2а/a2b
MX2017012430A (es) Formas solvatadas de un inhibidor de tirosina quinasa de bruton.
AU2020278236A8 (en) Methods of treating Sjögren&#39;s Syndrome using a Bruton&#39;s tyrosine kinase inhibitor
PH12021550549A1 (en) Dp antagonist
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MY206632A (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2022004121A (es) Derivados de homopiperazinil y homopiperidinil quinazolin-4(3h)-ona que tienen actividad multimodal contra el dolor.
MX2021004885A (es) Derivados de piperazinil y piperidinil-quinazolin-4(3h)-ona que tienen actividad contra el dolor.
TW200640904A (en) Quinazoline derivatives
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
EA201792170A1 (ru) Производные индола
GEAP202416375A (en) Pro drugs of pde10 compounds
UA95811C2 (en) 5,7-disubstituted [1,3]thiazolo [4,5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy